FIG 6.

Pre-treatment of ARPE-19 cells with the Lrp1-binding agent RAP reduces RVFV ZH501 infection. (A) ARPE-19 cells were treated with 10 μg/mL of RAP, a high-affinity Lrp1 ligand, 1 h prior to infection with MOI 0.1 of RVFV ZH501 and stained for RVFV N (magenta) and Lrp1 (green) at 24 hpi. Scale bar is 250 μm. (B) ARPE-19 cells with or without RAP pre-treatment were infected with MOI 0.1 of RVFV ZH501 or ZIKV as a control. Samples were collected at 24 hpi for RVFV and 48 hpi for ZIKV and analyzed by viral plaque assay. Data are representative of 2 experiments. Error bars are standard error mean. Statistics were determined by unpaired t test. **, P < 0.01.